Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma-Reference-Cited by-同舟云学术

Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma

Published:2016-01-02 Issue:1 Volume:34 Page:39-44
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Labussière Marianne,Cheneau Caroline,Prahst Claudia,Gállego Pérez-Larraya Jaime,Farina Patrizia,Lombardi Giuseppe,Mokhtari Karima,Rahimian Amithys,Delattre Jean-Yves,Eichmann Anne,Sanson Marc

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/07357907.2015.1088948

Reference22 articles.

1. Angiogenesis as a therapeutic target

2. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab;Investigative Ophthalmology & Visual Science;2024-09-09

2. Interleukin 6 and cancer resistance in glioblastoma multiforme;Neurosurgical Review;2024-09-05

3. A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies;Drug Development Research;2024-09

4. Identification of established and novel extracellular matrix components in glioblastoma as targets for angiogenesis and prognosis;Neurogenetics;2024-05-22

5. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma;ESMO Open;2024-04